MarginsXMarginsX
Home › Markets › Health Care › ALT

Altimmune Inc. (ALT)

ALT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.56
-5.17% on the day
Market cap
$303.6M
Small cap
Revenue · 2025
$41K
+105.0% on 2024
Net income · 2025
-$88.1M
-214861.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/0001326190-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerALT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001326190
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$41K
Net income-$88.1M
Operating income-$94.5M
Net margin-214861.0%
Operating margin-230461.0%
Revenue growth+105.0%
Cash$43.8M
Total assets$279.9M
P/E (computed)Net income was not positive
P/S (computed)7403.9×

Warning signs

Cash runway
3.4 months
$28.9M cash at September 30, 2026
Share count, 1 year
+86.6%
2025-10-31 to 2026-11-06 · +262.2% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$370K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$28.9M cash; operating cash flow -$25.6M a quarter.Report 2026-09-30
Shares outstanding194,589,451 (2026-11-06); 104,254,173 a year earlier; 53,728,871 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-04-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $370K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$31.6M-$37.7M$28.9M$35.0MNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$22.8M-$24.2M$63.0M$34.7MNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$22.6M-$20.9M$97.6M$34.5MNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
$26K-$27.4M-$19.4M$43.8M$34.3M$41K10-K 2026-03-06
Q3 2025
2025-09-30
$5K-$19.0M-$11.9M$61.2M$14.4M$20K10-Q 2026-11-12
Q2 2025
2025-06-30
$5K-$22.1M-$19.4M$183.1M$14.3M$20K10-Q 2026-08-12
Q1 2025
2025-03-31
$5K-$19.6M-$16.8M$49.1MNo debt tags$20K10-Q 2026-05-13
Q4 2024
2024-12-31
$5K-$23.2M-$18.3M$36.9MNo debt tags$20K10-K 2026-03-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-24
Latest annual report10-K2026-03-06
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-03-17

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-20.9%
1 month-32.3%
3 months-42.9%
Year to date-54.4%
1 year-59.5%
From 52-week high-73.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GALTGalectin Therapeutics Inc.$3.02-0.98%$305.2M
BNTCBenitec Biopharma Inc.$8.54-5.53%$308.5M
EBSEmergent BioSolutions Inc.$5.81+0.35%$298.7M
ENTAEnanta Pharmaceuticals Inc.$10.67-2.91%$310.8M
LRMRLarimar Therapeutics Inc.$3.00-0.66%$311.6M
EVMNEvommune Inc.$7.10-6.95%$293.6M
FULCFulcrum Therapeutics Inc.$3.71-1.59%$283.4M
AVIRAtea Pharmaceuticals Inc.$4.12-4.19%$330.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier